Description
Elafibranor is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have an inadequate response to ursodeoxycholic acid, or as monotherapy in people unable to tolerate ursodeoxycholic acid.
In June 2024, the US Food and Drug Administration (FDA) granted accelerated approval to elafibranor. The FDA considers it to be a first-in-class medication.
How to get access Iqirvo (elafibranor) for personal use ?
To get access to Iqirvo (elafibranor), you need a prescription from a doctor, as it is a prescription-only medication. Your prescription will be filled through a specialty pharmacy, which will handle insurance and coordinate delivery of the medication to you. Your doctor will also need to provide specific information for the prescription to be filled correctly.
However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Iqirvo (elafibranor) prices may fluctuate over time because of market dynamics and regulatory changes. It can be imported for personal use under “Named Patient Program” treatment in multiple countries, including the Singapore, Kuala Lumpur (Malaysia), Bangkok (Thailand), Jakarta, Surabaya, Bandung (Indonesia), Manila, Cebu (Philippines), Ho Chi Minh City, Hanoi (Vietnam), Yangon (Myanmar), Phnom Penh (Cambodia), Vientiane (Laos), UAE, Saudi Arabia, Argentina, Brazil, UK, Hungary, Ireland, Latvia, Slovakia, Czech Republic, Belgium, Lithuania, Greece, Spain, Zimbabwe, Australia, and New Zealand.
To order or inquire about Iqirvo (elafibranor) international access, you can contact Verve Biosciences – a trusted pharmaceutical exporter, supplier, and distributor of anti-cancer and specialty medications.
📧 Email: urgent@cancermedicinesnetwork.com
📞 Call or WhatsApp: 9910645395 or 9910645395
Note: Availability may vary by country and is subject to regulatory approvals.
